Table 4 Univariate and multivariate analysis of clinico-pathological parameters for the prediction of cancer-specific survival in patients with operable pancreatic cancer (n=110)
Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|
Parameter | HR (95% CI) | P -value | HR (95% CI) | P -value |
Gender | ||||
Female | 1 (referent) | 0.641 | 1 (referent) | 0.252 |
Male | 0.901(0.583–1.394) | 0.771 (0.494–1.203) | ||
Age at operation (years) | ||||
<65 | 1 (referent) | 0.102 | 1 (referent) | 0.066 |
⩾65 | 1.440 (0.930–2.229) | 1.522 (0.973–2.379) | ||
Stage at diagnosis | ||||
Stage I/IIa | 1 (referent) | <0.001 | 1 (referent) | 0.001 |
Stage IIb/III | 3.686 (2.006–6.770) | 2.923 (1.563–5.466) | ||
Treatment | ||||
No chemotherapy | 1 (referent) | 0.069 | NI | |
Chemotherapeutic treatment | 0.779 (0.596–1.020) | |||
Neutrophil-lymphocyte ratio | ||||
<5 | 1 (referent) | 0.006 | 1 (referent) | 0.039 |
⩾5 | 1.852 (1.198–2.865) | 1.611 (1.024–2.534) | ||
Glasgow prognostic score | ||||
0 | 1 (referent) | 0.585 | NI | |
1+2 | 1.095 (0.791–1.516) | |||
Platelet-lymphocyte ratio | ||||
<150 | 1 (referent) | 0.458 | NI | |
⩾150 | 1.133 (0.815–1.574) | |||
Resection margin | ||||
R0 | 1 (referent) | 0.019 | 1 (referent) | 0.073 |
R1 | 1.884 (1.110–3.199) | 1.699 (0.951–3.035) |